济川药业：鼾眠颗粒临床试验默示许可 即将启动临床试验

Core Viewpoint - Jichuan Pharmaceutical has received clinical trial approval for its innovative traditional Chinese medicine, Hanmian Granules, aimed at treating pediatric adenoid hypertrophy and related conditions [1] Group 1: Company Developments - Jichuan Pharmaceutical's wholly-owned subsidiary, Jichuan Pharmaceutical Group Co., Ltd., in collaboration with Shandong Kangzhonghong Pharmaceutical Technology Development Co., Ltd., has jointly applied for the clinical trial of Hanmian Granules [1] - The clinical trial has received an implied approval from the National Medical Products Administration, with acceptance number CXZL2500077, and is set to commence soon [1] Group 2: Product Information - Hanmian Granules is classified as a Class 1 innovative traditional Chinese medicine [1] - The product is indicated for pediatric patients suffering from adenoid hypertrophy, lung and spleen qi deficiency, and phlegm-stasis syndrome [1]